Mylan's $73.5 million settlement in US antitrust case over EpiPen granted final approval
MLex Summary: Mylan’s $73.5 million settlement to resolve US antitrust claims accusing it of conspiring to block access to generic versions of EpiPen has been granted final approval by a federal...To view the full article, register now.
Already a subscriber? Click here to view full article